Consensus Lundbeck Nasdaq Copenhagen

Stocks

LUN

DK0061804697

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 19:20:00 21/08/2026 +04			5-day change	1st Jan Change
40.50 ^DKK	+0.50%		+12.50%	+11.88%

08-20	Cancer vaccines finally garner the spotlight
08-20	UBS raises Lundbeck price target to 45 Danish kroner (44), reiterates neutral	FW

Evolution of the Average Target: Lundbeck

Evolution of the Target Price: Lundbeck

Changes in Analyst Recommendations: Lundbeck

47.YYRIAkK7pha_z86QnuUt-sWFKdEfbwoqFHRQAsxii0k.ObwjTgHu6XjHq4nixNx4wvP3aOVMHXpIdxghN5NauxAYxj1hDt_wI8aE_g~e39ec89183b49b1b2bfaac5db2e8d844

Analysts' recommendations: Lundbeck

08-20	Cancer vaccines finally garner the spotlight
08-20	UBS raises Lundbeck price target to 45 Danish kroner (44), reiterates neutral	FW
08-19	H Lundbeck: Q2 beat, but pipeline execution remains non-negotiable
08-17	Lundbeck expected to report DKK 1,945m in adjusted EBITDA, consensus	FW
07-17	Barclays raises price target for Lundbeck to 48 Danish kroner (45), reiterates equal weight - BN	FW
07-14	Where would AI lead Pharma in the long run?
07-13	Danske Bank raises Lundbeck price target to 57 Danish kroner (55), reiterates buy - BN	FW
06-18	Nordea raises target price for Lundbeck to DKK60 (57), reiterates buy rating	FW
05-13	H Lundbeck: Strong Q1, but long-term growth uncertainty hovers over valuation
05-13	Nordea raises Lundbeck price target to DKK 57 (55), reiterates Buy	FW
05-13	DNB Carnegie raises Lundbeck price target to DKK 54 (53), reiterates Buy	FW
04-28	SEB raises Lundbeck price target to DKK 46 (43), reiterates Hold	FW
04-27	UBS raises Lundbeck price target to DKK 44 (42), reiterates Neutral	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT
03-20	H Lundbeck: Markets need more proof of growth promise
03-05	Nordea Resumes Coverage of Lundbeck With Buy Rating – Too Cheap to Ignore	FW
03-05	Nordea Resumes Coverage of Lundbeck with Buy Rating and Price Target of 55 Danish Kroner	FW
03-02	Jefferies Upgrades Lundbeck to Hold (Underperform), Sets Price Target at 39 Danish Kroner	FW
02-17	Deutsche Bank Lowers Price Target for Lundbeck to 40 Danish Kroner (44), Maintains Hold Recommendation	FW
02-16	DNB Carnegie Raises Price Target for Lundbeck to 53 Danish Kroner (51), Reiterates Buy	FW
02-12	Barclays Lowers Price Target for Lundbeck to 45 Danish Kroner (from 50), Maintains Equal Weight - BN	FW
02-06	H Lundbeck: Weak 2026 outlook a turn-off for investors
02-05	Danske Bank Lowers Price Target for Lundbeck to 48 Danish Kroner (52), Reiterates Buy - BN	FW
02-05	UBS Lowers Price Target for Lundbeck to 42 Danish Kroner (46), Reiterates Neutral Rating	FW
02-05	SEB Lowers Price Target for Lundbeck to 43 Danish Kroner (from 50), Maintains Hold Recommendation	FW

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
MCKESSON CORPORATION		+14.91%
CARDINAL HEALTH, INC.		+18.05%
SIGMA HEALTHCARE LIMITED		+13.84%
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD		+27.53%
HUADONG MEDICINE CO., LTD		+64.51%
SINOPHARM GROUP CO. LTD.		+36.84%
H. LUNDBECK A/S		+17.47%
GALENICA AG	-	+6.89%
JOINTOWN PHARMACEUTICAL GROUP CO., LTD		+19.35%
Average		+24.38%
Weighted average by Cap.		+18.38%